Our executive team of biopharma industry veterans have a record of scientific excellence and deep experience in making medicines available to the patients who need them.
Richard Lowenthal, M.S., M.B.A.
Richard Lowenthal is the president, chief executive officer and co-founder of ARS Pharmaceuticals, Inc.
With more than 25 years of biotechnology and pharmaceutical development experience in various roles at both small and large companies, Lowenthal is a seasoned executive with expertise in strategic drug and global development, project leadership, regulatory affairs, quality assurance and product registration of new drugs and biologics in the United States, Europe and Japan.
Dedicated to the support of pharmaceutical, biotechnology and investment companies, in 2007 Lowenthal founded Pacific-Link Regulatory Consulting, where he provides leadership and mentoring on regulatory affairs, clinical development, quality assurance, licensing and investment opportunities. He has also led regulatory efforts at Neurelis since its inception.
Prior to ARS Pharmaceuticals, Inc., Lowenthal held many leadership roles that included vice president of regulatory affairs and quality assurance for Cadence Pharmaceuticals; head of worldwide regulatory affairs, quality assurance and drug safety for Maxim Pharmaceuticals, Inc.; vice president of regulatory affairs and quality assurance for AnGes, MG, Inc.; global project leader and global director of regulatory affairs for Janssen Research Foundation; director of regulatory affairs and quality assurance for Somerset Pharmaceuticals Inc.; and new drug review chemist for the U.S. Food and Drug Administration in the division of neuropharmacologic drug products and the division of oncology and pulmonary drug products.
Lowenthal holds an M.S. in organic chemistry from Florida State University and an M.S. in executive leadership from the University of San Diego. He has served as past chair of the American Association of Pharmaceutical Scientists (San Diego region), as well as member of the USP Biotechnology Expert Committee, chair of the Virology Working group, member of the National Organization of Rare Disease Corporate Council and has worked with various PhARMA and ICH Working Groups.
Robert Bell, Ph.D.
Dr. Robert Bell is the chief scientific officer of ARS Pharmaceuticals, Inc. He brings more than 30 years of multidisciplinary experience in strategic global business development, product registration and commercialization of new drugs, biologics, devices and generic drug products. Dr. Bell also has extensive expertise with global business collaborations and product development efforts that have resulted in product approvals and new market opportunities.
Prior to joining ARS Pharmaceuticals, Inc., Dr. Bell held various leadership positions in the pharmaceutical industry, serving as vice president, new / strategic drug development at Barr Laboratories, Inc.; vice president, research, development and quality at Somerset Pharmaceuticals, Inc.; vice president, research and development at UDL Laboratories, Inc.; director, research and development at AL Pharma and senior chemist at Carter-Wallace, Inc.
Dr. Bell is an affiliate professor of pharmacy at the College of Pharmacy at the Medical College of Virginia, Virginia Commonwealth University and an adjunct professor of Pharmaceutics, a member of the National Advisory Board and recipient of the Distinguished Alumnus Award from the College of Pharmacy, University of Florida. He also been published and has issued eight patents with several pending.
Dr. Bell is a member of the Council of Experts, General Chapters-Biological Analysis and the Joint Standards Subcommittee for United States Pharmacopeia, the American Society of Clinical Oncology, American Urology Association, International Society of Andrology, American College of Clinical Pharmacology and American Chemical Society. He is also an editorial advisory board member for the Journal of Chemical and Pharmaceutical Sciences and Enliven: Biosimilars and Bioavailability and co-editor for the book Poorly Soluble Drugs: Dissolution and Drug Release. He is also the past chair of the Analysis and Pharmaceutical Quality section for the American Association of Pharmaceutical Scientists, where he served in various leadership capacities.
Harris Kaplan, M.B.A.
Harris Kaplan is the chief marketing officer at ARS Pharmaceuticals, Inc. Harris brings more than 40 years of industry marketing strategy consulting experience and has worked on the introduction of more than 100 new products across pharmaceutical, diagnostic, and device markets. His recent experience includes supporting Kite Pharmaceuticals in the launch of Yescarta, Vertex in the launch of its cystic fibrosis compounds, Austedo for Teva, and Cologuard for Exact Sciences.
Kaplan is an expert at product positioning and segmentation, identifying unique and actionable opportunities that have resulted in significant value creation for clients and their investors. He has a deep understanding of the changes and requirements surrounding the launch of new products in life sciences and has been a frequent speaker and author on Creating a Compelling Product Value Proposition in this challenging innovation environment. Harris was elected to the 100 most inspirational people by Pharma Voice in 2011.
Kaplan, who serves as the Managing Partner of Red Team Associates and the President and Chief Executive Officer of Healogix, also co-founded Migliara-Kaplan Associates which became the largest marketing research and consulting group before it was acquired by Interpublic Group, now part of Kantar and was also a co-founder of Cozint Interactive, acquired by GFK Healthcare. He is an advisor to several venture capital funds, and sits on the Board of Directors of the Kernan Orthopedic Hospital and the Giving Hope Network which focuses on providing school materials and clothing for poor inner, city children in New Jersey and Philadelphia.
Kaplan received his B.B.A in Business Administration and his M.B.A. in Marketing and Operations Research from Temple University.
Sarina Tanimoto, M.D., M.B.A.
Dr. Sarina Tanimoto is a co-founder and chief medical officer at ARS Pharmaceuticals, Inc., offering more than 18 years of pharmaceutical experience in clinical drug development, including participating in the approval of several medicines.
Prior to joining ARS Pharmaceuticals, Inc., Dr. Tanimoto was chief medical officer at Pacific-Link Regulatory Consulting for eight years. In this role, she supported multiple programs from Phase 1 to Phase 3 clinical trials in various therapeutic areas, including several intranasal products. Before that, Dr. Tanimoto held roles in clinical and business development during her tenure at AnGes Inc. She has also served as a clinical scientist at Roche, where she was involved in global clinical development.
Dr. Tanimoto earned an M.D. from University of Toyama, followed by internal medicine training at the National Center for Global Health and Medicine in Tokyo. She holds an M.B.A. from McGill University.
Brian T. Dorsey, MSc.
Brian Dorsey is the senior vice president of operations and project management at ARS Pharmaceuticals, Inc. He has served in the pharmaceutical and biotechnology industries for more than 20 years providing high-level drug development, regulatory and QC/QA leadership of pharmaceutical candidates from early development through FDA approval.
Dorsey is a founding partner at MagnaSci Ventures, a healthcare fund focused on investing in early stage life science companies. He is also a founder of Kalyra Pharmaceuticals and Septum Solutions. Prior to joining ARS Pharmaceuticals, Inc., Dorsey was chief development officer for Apricus BioSciences, a publicly traded biotechnology company.
Dorsey has also held various senior management positions including senior vice president of research and development and chief compliance officer of Pernix Therapeutics Holding Inc.; senior vice president of technical operations and regulatory affairs for Somaxon Pharmaceuticals; head of project management, medical writing and library services at Maxim Pharmaceuticals; head of biopharmaceutical project management of Baxter Bioscience and manager of chemistry, manufacturing, and control for Chugai Biopharmaceuticals.
Dorsey has held several positions within the Agouron / Warner Lambert/ Pfizer organization and has lead development projects in the antiviral, oncology, and ophthalmology therapeutic areas. He was named a Global Project Leader within Pfizer.
He serves on the board of directors for Neurana Pharmaceuticals, Cell Machines, Forward Sciences, Forge Therapeutics and Tao Life Sciences.
Dorsey received his Master of Science in Executive Leadership and his B.A. in chemistry from the University of San Diego.
Dana McGowan is the chief financial officer at ARS Pharmaceuticals, Inc. She brings extensive financial experience in the biotechnology and high technology industries that spans fundraising, investor relations, financial strategy and financial operations.
McGowan provides financial consulting services as acting chief financial officer for clinical-stage biotechnology companies Antiva Biosciences, Inc. and Lyric Pharmaceuticals, Inc. Previously, McGowan was chief financial officer for Ocera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and liver disease. Before that, she served as vice president of finance and administration and chief financial officer for MedVantx, a healthcare technology company, Kinzan, Inc., an internet company, and DepoTech Corporation, a public drug delivery company. McGowan has also held various financial positions with Cytel Corporation, a public biotechnology company focused on immunology and carbohydrates, and SAIC, a Fortune 500 technical services company. >Her financial experience includes venture and debt financing, IPOs and follow-on offerings, corporate partnering and mergers and acquisitions.
McGowan holds a B.S. in business administration from San Diego State University and is a certified public accountant (inactive). She has been a Springboard Panel Member for UCSD Connect, a donation and flexible event chair for Teen Volunteers in Action and is a former member of the CFO Steering Committee of UCSD Connect/Athena.